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Summary
Background.— Improvements in the treatment of coronary artery disease mean that an increas-
ing number of patients survive acute cardiovascular events and live as outpatients with or
without anginal symptoms.
Aim.— To determine the characteristics and management of contemporary outpatients with
stable coronary artery disease in Western Europe, and to compare France with the other Western
European countries.
Methods.— CLARIFY (prospeCtive observational LongitudinAl RegIstry oF patients with stable
coronary arterY disease) is an international, prospective, observational, longitudinal study.
Between November 2009 and July 2010, 32,954 adult outpatients with stable coronary artery
disease (deﬁned as a history of documented myocardial infarction [of > 3months], prior coronary
revascularization, chest pain with myocardial ischaemia, or coronary stenosis of > 50% proven
by angiography) were enrolled in 45 countries. The demographics and management of CLARIFY
patients enrolled in France were compared with those enrolled in other Western European
countries (Austria, Belgium, Denmark, Germany, Greece, Ireland, Italy, Netherlands, Portugal,
Spain, Switzerland and the UK).
Results.— Of the 14,726 patients enrolled in Western Europe (mean age 66.2 [10.2] years;
79.6% male), 2432 (16.5%) were from France. The use of aspirin was lower in France than in
other Western European countries (74.5% vs. 86.9%, respectively), whereas use of thienopy-
ridines (48.5% vs. 21.7%), oral anticoagulants (12.3% vs. 9.0%) and lipid-lowering drugs (95.8%
vs. 92.5%) was higher. Beta-blockers were used in 73% of both groups. Angina was less prevalent
in France (6.3% vs. 15.5%) and French patients showed higher levels of physical activity than
their counterparts in Western Europe.
Conclusions.— The management of patients with stable CAD in France appears favourable, with
good adherence to guideline-based therapies, but there remains room for improvement in terms
of symptom and risk factor control.
© 2014 Published by Elsevier Masson SAS.
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Résumé
Contexte.— Les améliorations dans le traitement de la maladie coronaire impliquent qu’un
nombre croissant de patients survivent après un événement coronaire aigu et deviennent des
patients ambulatoires avec ou sans symptômes angineux.
Objectif.— Déterminer les caractéristiques et la prise en charge des patients ambulatoires
porteurs d’une maladie coronaire stable en Europe de l’Ouest et comparer les patients franc¸ais
avec les patients des autres pays européens.
Méthodes.— CLARIFY (ProspeCtive observational LongitudinAl RegIstry oF patients with stable
coronary arterY disease) est une étude internationale longitudinale prospective et observa-
tionnelle. Entre novembre 2009 et juillet 2010, 32 954 patients adultes porteurs d’une maladie
coronaire stable (déﬁnie comme des patients ayant une histoire d’infarctus du myocarde docu-
menté de plus de 3mois, un antécédent de revascularisation coronaire, des douleurs thoraciques
avec une ischémie myocardique ou une sténose coronaire de plus de 50% démontrée par une
coronarographie) ont été inclus dans 45 pays. Les caractéristiques démographiques et la prise en
charge des patients CLARIFY inclus en France ont été comparés avec celles des patients inclus
dans les autres pays d’Europe de l’Ouest (Autriche, Belgique, Danemark, Allemagne, Grèce,
Irlande, Italie, Pays-Bas, Portugal, Espagne, Suisse et le Royaume-Uni).
Résultats.— Parmi les 14 726 patients inclus en Europe de l’Ouest (moyenne d’âge : 66,2 [10,2]
ans ; 79,6 % d’hommes), 2432 (16,5 %) étaient des patients franc¸ais. L’utilisation d’aspirine était
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plus basse en France que dans les autres pays européens de l’Ouest (74,5 % vs 86,9 %, respective-
ment) tandis que l’utilisation des thiénopyridines (48,1 % vs 21,7 %), les anticoagulants oraux
(12,3 % vs 9,0 %) et les traitements hypolipidémiants (95,8 % vs 92,5 %) étaient plus élevés. Les
bêtabloqueurs étaient utilisés chez 73% des patients des deux groupes. L’angine de poitrine
était moins prévalente en France (6,3 % vs 15,5 %) et les patients franc¸ais présentaient un plus
haut niveau d’activité physique par rapport aux autres patients d’Europe de l’Ouest.
Conclusion.— La prise en charge des patients porteurs d’une maladie coronaire stable en France
semble appropriée, avec une bonne adhésion aux thérapeutiques recommandées, mais il reste
des améliorations à faire aﬁn de contrôler les symptômes et les facteurs de risque.
© 2014 Publié par Elsevier Masson SAS.
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trocardiography, using the most recent electrocardiogram
within 6months in clinically stable patients), laboratory val-ntroduction
espite substantial improvements in preventive cardiology,
oronary artery disease (CAD) remains the leading cause of
eath and morbidity worldwide [1—3] and in Europe [4].
econdary prevention of acute coronary syndromes has also
dvanced, with a series of large, randomized clinical tri-
ls establishing the value of antiplatelet therapy, statins,
nd angiotensin-converting enzyme inhibitors in this setting
5,6]. CAD places a major burden on public health [7—9], due
ot only to an ageing population, but also to the increasing
umbers of patients who survive an initial acute cardiovas-
ular event and live as outpatients, with or without anginal
ymptoms [5,6,10,11], and who are at high risk of myocardial
nfarction, heart failure, arrhythmia, and death. Important
eterminants of long-term CAD survival include risk factors
nd their management, including left ventricular function,
xtent of artery disease, heart rate [12—14], and treatment
15].
Important changes in the management and outcomes of
atients with CAD mean that a need has arisen for cur-
ent data in patients with stable CAD treated in everyday
ractice. It is important to have longitudinal observations
f a large, representative cohort of patients, spanning sev-
ral geographical regions, focusing on stable outpatients,
nd including both symptomatic and asymptomatic individ-
als. The prospeCtive observational LongitudinAl RegIstry oF
atients with stable coronary arterY disease (CLARIFY) was
nitiated to improve our knowledge about the contemporary
table CAD population [16,17]. The aim of this analysis was
o compare the characteristics and management of CLAR-
FY patients from France with those from patients in other
estern European countries.
ethods
tudy design
LARIFY is an international, prospective, observational, lon-
itudinal registry in outpatients with stable CAD, followed
p for 5 years. The study rationale and methods have been
ublished previously [16]. Patients were enrolled between
ovember 2009 and July 2010 in 45 countries in Africa, Asia,
ustralia, Europe, the Middle East, and North, Central and
outh America.
u
(
iThe registry is being performed in accordance with the
rinciples of the Declaration of Helsinki and has been
pproved by local institutional review boards. All patients
ave written informed consent to participate in agreement
ith national and local guidelines. Patient conﬁdentiality
s ensured by the use of patient identiﬁcation code num-
ers that correspond to computer ﬁles. As an observational
tudy, the management and treatment of patients is con-
ucted according to usual practices, with no speciﬁc tests
r therapies deﬁned in the study protocol.
tudy population
ligible subjects were outpatients with stable CAD demon-
trated by a history of at least one of the following
riteria: documented myocardial infarction (> 3months
reviously); coronary stenosis > 50% proven by coronary
ngiography; chest pain with myocardial ischaemia proven
y stress electrocardiogram, stress echocardiography, or
yocardial imaging; or coronary artery bypass graft or
ercutaneous coronary intervention performed > 3months
reviously.
Patients were excluded from participation if they had
een hospitalized for cardiovascular disease within the
revious 3months (including for revascularization), were
lanned to undergo revascularization, or had a condition
xpected to hamper participation up to 5 years (e.g. limited
ooperation or legal capacity, serious non-cardiovascular
isease, a condition that could affect life expectancy [e.g.
ancer, drug abuse], or severe cardiovascular disease [e.g.
dvanced heart failure, severe valve disease, history of
alve repair/replacement]).
valuations
aseline data were collected anonymously using elec-
ronic case report forms. Information documented included
atient demographics, medical history, risk factors, employ-
ent status, the results of physical examination, heart
ate (determined by both pulse palpation and 12-lead elec-es (if available), and current chronic medical treatments
i.e. taken regularly for≥ 7 days before entry into the reg-
stry).
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Figure 1. Patient ﬂow chart.
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lManagement of stable CAD in France
Study setting and site selection
To ensure that the population was representative of the real-
life community of stable CAD outpatients, recruitment of
sites and patients was based on the predeﬁned selection
of physician types and consecutive enrolment of eligible
patients. In each country participating in CLARIFY, the types
(ofﬁce-based primary care physicians, internists, physicians
based in hospitals with outpatient clinics, cardiologists, or
other specialties) and practice settings (hospital-based as
opposed to ambulatory practice) of physicians in charge
of CAD patients was determined, using the best avail-
able epidemiological data and market research data. This
allowed targeting of an appropriate proportion of each of
these physician types and settings, and provided a distri-
bution of physicians (and therefore of patient populations)
across regions and locations (urban, suburban, or rural) that
reﬂected the epidemiological patterns in each country. The
national coordinator in each country also reviewed the site
selection. Each physician recruited, over a brief period of
time, 10—15 outpatients with stable CAD.
Data management and quality
Data were collected centrally using a standardized, interna-
tional case report form (translated into the local language)
and sent by each country to the data management centre
(Robertson Centre for Biostatistics, University of Glasgow,
UK) where checks for completeness, internal consistency,
and accuracy were run. Data quality control is performed
annually onsite in 1% of randomly selected sites up to
5 years. At these sites, 100% of case report forms for patients
enrolled at that site were monitored for source docu-
mentation and accuracy. Data quality control was done at
face-to-face quality control visits, and involved review of
source documents supporting the adequacy and accuracy of
data collected on the case report forms.
In this analysis, the data from patients enrolled in France
were compared with those enrolled in the other West-
ern European countries participating in CLARIFY (Austria,
Belgium, Denmark, Germany, Greece, Ireland, Italy, Nether-
lands, Portugal, Spain, Switzerland, UK).
Statistical analysis
Data were analysed by an independent statistics centre at
the Robertson Centre for Biostatistics. Baseline variables
are summarized as mean (standard deviation) or median
(interquartile range) for continuous data, depending on the
distribution of the data, and as counts and percentages for
categorical data, and were based on patients in whom data
were available. Comparisons between patients in France and
those in Western Europe were made using one-way ANOVA
or the Kruskal-Wallis test for continuous variables, again
depending on the distribution of the data, and Pearson’s Chi2test or Fisher’s exact test for categorical variables. All anal-
yses were performed using SAS version 9.2. A signiﬁcance
level of 0.05 was used to test for statistical differences; all
tests used were two-sided.
t
f
h
lnstitutional review board (IRB).
esults
tudy population
f the 33,428 outpatients screened, 18,702 were excluded
rom the present analysis for one of the following reasons:
01 did not provide written informed consent, 42 did not
eet the inclusion or exclusion criteria, in 331 patients
nformed consent or institutional review board approval
as not ascertained or veriﬁable, and 18,228 patients
ere enrolled outside of Western Europe. Of the remaining
4,726 patients, 12,294 were from Western Europe (exclud-
ng France) and 2432 were from France (Fig. 1). Patient
nrolment in France took place between May and July 2010.
The mean age of the Western European population
as 66.2 (10.2) years and 79.6% were male. The baseline
haracteristics of the outpatients, classiﬁed according to
nrolment in France or other Western European country, are
etailed in Table 1. French patients were, on average, more
requently male (83.7% vs. 78.8%) and slightly older (66.7
s. 66.1 years), and had a lower mean heart rate (64.6 vs.
6.5 beats per minute [bpm] on palpation) and higher left
entricular ejection fraction (59.3% vs. 56.9%) than patients
n other Western European countries. French patients were
ess likely than those in other Western European countries
o have treated hypertension (57.7% vs. 69.8%), to have a
amily history of premature CAD (24.7% vs. 29.6%) or to
ave congestive heart failure (2.9% vs. 7.9%), but were more
ikely to have dyslipidaemia (79.6% vs. 76.0%). A minority of
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Table 1 Characteristics of the study population classiﬁed according to France vs. Europe.
Parameter Patients with data France
(n = 2432)
Europe
(n = 12,294)
P-value
Age (y), mean (SD) 14,701 66.7 (10.7) 66.1 (10.0) 0.0057
Men, n (%) 14,703 2031 (83.7) 9675 (78.8) < 0.0001
BMI (kg/m2), median (IQR) 14,691 26.8 (24.5, 29.7) 27.7 (25.4, 30.5) < 0.0001
Risk factors
Diabetes mellitus, n (%) 14,705 619 (25.5) 3272 (26.6) 0.25
Dyslipidaemia, n (%) 14,707 1930 (79.6) 9333 (76.0) 0.0001
Family history of CADa, n (%) 14,707 600 (24.7) 3634 (29.6) < 0.0001
Treated hypertension, n (%) 14,707 1400 (57.7) 8578 (69.8) < 0.0001
Presentation characteristics
HR palpation (bpm), mean
(SD)
14,679 64.6 (9.9) 66.5 (10.6) < 0.0001
HR ECG (bpm), mean (SD) 11,564 63.5 (10.2) 65.9 (11.3) < 0.0001
SBP (mmHg), mean (SD) 14,686 131.3 (14.1) 131.5 (16.4) 0.75
DBP (mmHg), mean (SD) 14,686 75.5 (8.4) 76.6 (9.5) < 0.0001
Controlled blood pressure
(SBP < 140/DBP < 90mmHg)
14,686 1658 (68.9) 7903 (64.4) < 0.0001
LVEF (%), mean (SD) 10,234 59.3 (10.1) 56.9 (10.8) < 0.0001
Creatinine (mmol/L), median
(IQR)
11,146 0.09 (0.08, 0.10) 0.09 (0.08, 0.10) 0.96
Total cholesterol (mmol/L),
median (IQR)
11,678 4.3 (3.8, 4.9) 4.3 (3.7, 4.9) 0.21
LDL-cholesterol 10,005 2.3 (2.0, 2.8) 2.4 (1.9, 2.9) 0.08
LDL, n (%) 10,005
< 70mg/dL
(< 1.82mmol/L)
364 (18.4) 1611 (20.1) < 0.0001
70—100mg/dL
(1.82—2.60mmol/L)
925 (46.8) 3323 (41.4)
> 100mg/dL
(> 2.60mmol/L)
688 (34.8) 3094 (38.5)
High-density lipoprotein
cholesterol
10,884 1.2 (1.0, 1.5) 1.2 (1.0, 1.4) <0.0001
CHF symptoms including NYHA
class, n (%)
14,704
No CHF 2352 (97.1) 11,313 (92.1) < 0.0001
Class II 53 (2.2) 813 (6.6)
Class III 18 (0.7) 155 (1.3)
Current evidence of
myocardial ischaemia, n (%)
14,692 300 (12.4) 2277 (18.6) < 0.0001
Medical history
Peripheral artery disease, n
(%)
14,706 426 (17.6) 1408 (11.5) < 0.0001
Myocardial infarction, n (%) 14,706 1304 (53.8) 7114 (57.9) 0.0002
Stroke, n (%) 14,706 59 (2.4) 428 (3.5) 0.0081
PCI, n (%) 14,707 1758 (72.5) 7322 (59.6) < 0.0001
CABG, n (%) 14,707 547 (22.6) 3277 (26.7) < 0.0001
Pacemaker, n (%) 14,707 94 (3.9) 365 (3.0) 0.019
Hospitalization for CHF, n (%) 14,707 111 (4.6) 464 (3.8) 0.06
Atrial ﬁbrillation/ﬂutter, n (%) 14,707 209 (8.6) 1041 (8.5) 0.82
Asthma/COPD, n (%) 14,707 217 (8.9) 1185 (9.6) 0.28
Reimbursement of
cardiovascular agents, n (%)
14,665
Fully reimbursed 2359 (97.8) 6684 (54.5) < 0.0001
Partly reimbursed 51 (2.1) 4281 (34.9)
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Table 1 (Continued)
Parameter Patients with data France
(n = 2432)
Europe
(n = 12,294)
P-value
Not reimbursed 1 (0.04) 1289 (10.5)
Lifestyle characteristics
Smoking status, n (%) 14,708
Current 250 (10.3) 1428 (11.6) 0.12
Former 1221 (50.4) 6207 (50.5)
Never 954 (39.3) 4648 (37.8)
Alcohol intake (number of
drinks per week), n (%)
14,706
0 836 (34.5) 4118 (33.5) 0.61
> 0 and < 20 1469 (60.6) 7528 (61.3)
≥ 20 119 (4.9) 636 (5.2)
Stimulant drinks consumed, n
(%)
14,705
Coffee 1550 (64.0) 7204 (58.7) < 0.0001
Tea 187 (7.7) 2442 (19.9)
Neither 686 (28.3) 2636 (21.5)
Physical activity, n (%) 14,703
None 353 (14.6) 2194 (17.9) < 0.0001
Light physical activity most
weeks
969 (40.0) 6126 (49.9)
≥ 20min vigorous physical
activity 1—2 times/week
583 (24.1) 2116 (17.2)
≥ 20min vigorous physical
activity≥ 3 times/week
516 (21.3) 1846 (15.0)
BMI: body mass index; CABG: coronary artery bypass graft; CAD: coronary artery disease; CHF: congestive heart failure; COPD: chronic
obstructive pulmonary disease; DBP: diastolic blood pressure; ECG: electrocardiogram; HR: heart rate; HRT: hormone replacement
therapy; IQR: interquartile range; LDL: low-density lipoprotein; NYHA: New York Heart Association; PCI: percutaneous coronary
intervention; SBP: systolic blood pressure; SD: standard deviation; bpm: beats per minute; y: year.
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oMyocardial infarction, sudden death, stable angina at age < 55 y
patients achieved low-density lipoprotein cholesterol con-
centrations of < 1.8mmol/L (< 70mg/dL) (18.4% in France vs.
20.1% in other Western European countries). French patients
also had a less frequent history of myocardial infarction
(53.8% vs. 57.9%) and stroke (2.4% vs. 3.5%), but were more
likely to have peripheral artery disease (17.6% vs. 11.5%).
They were also more likely to have undergone a previ-
ous percutaneous coronary intervention (72.5% vs. 59.6%),
whereas coronary artery bypass grafting was less frequently
performed (22.6% vs. 26.7%). French patients showed higher
levels of physical activity.
Angina was infrequent in French patients, and was more
than twice as prevalent in the other Western European group
(6.3% vs. 15.5%; Fig. 2). Of the patients with symptoms,
88.2% (n = 135) in France and 85.7% (n = 1630) in the other
Western European countries reported no or slight limitation
of ordinary physical activity (Canadian Cardiovascular Soci-
ety [CCS] class I or II), 12% in both groups reported marked
limitation (CCS class III), and a small percentage (1.8%) of
those in Western Europe reported CCS class IV.Chronic medication use
The use of selected chronic cardiovascular and non-
cardiovascular medications at enrolment is detailed in
b
t
i
lmen) or < 65 years (women) in a ﬁrst-degree relative.
able 2. Overall use of antiplatelet therapy was high,
ith aspirin being the most frequently used drug (84.8%
f patients); thienopyridines were used in 26.2% of the
uropean patients, but with a much higher rate of use in
rance versus the other countries (48.5% vs. 21.7%). Dual
ntiplatelet therapy (DAPT) was used in 30.7% of French
atients versus 22.4% of those in the other countries; corre-
ponding data for patients with a history of PCI were 38.0%
nd 30.9%, respectively (Table 3). Similarly, oral antico-
gulants were used more frequently in France (12.3% vs.
.0%; Table 2). The use of lipid-lowering drugs was also
igh overall, with a signiﬁcantly more frequent rate among
he French group (95.8% vs. 92.5%), whereas angiotensin-
onverting enzyme inhibitors or angiotensin II receptor
lockers were used slightly less frequently in France (73.0%
s. 75.7%).
Almost three-quarters of the patients (72.5%) were tak-
ng beta-blockers, and 17.7% had symptoms indicative of
ntolerance or a contraindication to beta-blocker therapy
Table 2). The rates of use of beta-blockers in patients with
r without a previous myocardial infarction did not differ
etween the two groups. The French group more commonly
ook calcium antagonists (29.6% vs. 24.6%), whereas use of
vabradine (10.6% vs. 13.2%) and long-acting nitrates was
ower (10.2% vs. 20.0%).
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Table 2 Selected cardiovascular and non-cardiovascular chronic medications: France vs. Europe.
Medication, n (%) Patients with data France
(n = 2432)
Europe
(n = 12,294)
P-value
Cardiovascular medications
Aspirin 14,700 1804 (74.5) 10,667 (86.9) < 0.0001
Thienopyridine 14,684 1175 (48.5) 2665 (21.7) < 0.0001
Other antiplatelet 14,683 110 (4.6) 1031 (8.4) < 0.0001
No or any antiplatelet 14,701 < 0.0001
No antiplatelet 94 (3.9) 701 (5.7)
1 antiplatelet 1585 (65.4) 8827 (71.9)
≥ 2 antiplatelets 744 (30.7) 2750 (22.4)
Oral anticoagulant 14,699 299 (12.3) 1106 (9.0) < 0.0001
Beta-blocker 14,700 1764 (72.8) 8900 (72.5) 0.76
In patients with previous MI 8414 1010 (77.6) 5383 (75.7) 0.14
In patients without previous MI 6284 754 (67.3) 3515 (68.1) 0.59
Intolerance or contraindication
to beta-blocker therapy
14,696 499 (20.6) 2105 (17.2) < 0.0001
Ivabradine 14,700 258 (10.6) 1625 (13.2) 0.0005
Calcium antagonist 14,698 717 (29.6) 3016 (24.6) < 0.0001
Verapamil or diltiazem 14,698 246 (10.2) 692 (5.6) < 0.0001
ACE or ARB 14,700 1769 (73.0) 9289 (75.7) 0.0064
Lipid-lowering druga 14,700 2321 (95.8) 11,362 (92.5) < 0.0001
Long-acting nitrate 14,698 247 (10.2) 2452 (20.0) < 0.0001
Other antianginal agent 14,694 342 (14.1) 643 (5.24) < 0.0001
Diuretic 14,697 640 (26.4) 3824 (31.2) < 0.0001
Other antihypertensive agentb 14,695 120 (5.0) 903 (7.4) < 0.0001
Digoxin and derivative 14,698 19 (0.8) 286 (2.3) < 0.0001
Amiodarone or dronedarone 14,693 128 (5.3) 308 (2.5) < 0.0001
Other antiarrhythmic drug 14,692 42 (1.7) 110 (0.9) 0.0002
Other medications
NSAID 14,695 50 (2.1) 696 (5.7) < 0.0001
Antidiabetic agent 14,699 579 (23.9) 2770 (22.6) 0.15
Thyroid HRT 14,698 93 (3.8) 748 (6.1) < 0.0001
Proton pump inhibitor 14,698 746 (30.8) 4565 (37.2) < 0.0001
HRT (postmenopausal women) 14,694 6 (0.2) 51 (0.4) 0.23
Erectile dysfunction 14,697 78 (3.2) 252 (2.1) 0.0004
ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker; CAD: coronary artery disease; CCS: Canadian Cardiovascular
Society; HRT: hormone replacement therapy; NSAID: non-steroidal anti-inﬂammatory drug; MI: myocardial infarction.
a Statins, ﬁbrates, niacin, ezetimibe.
b Alpha-blockers, central adrenergic stimulants.
Table 3 Use of antiplatelet therapies in patients with a history of percutaneous coronary intervention: France vs.
Europe.
Medication, n (%) Patients with data France
(n = 1758)
Europe
(n = 7322)
P-value
Aspirin 9075 1318 (75.1) 6573 (89.8) < 0.0001
Thienopyridine 9065 981 (55.9) 2063 (28.2) < 0.0001
Other antiplatelet 9063 90 (5.1) 707 (9.7) < 0.0001
No or any antiplatelet 9075 < 0.0001
No antiplatelet 47 (2.7) 266 (3.6)
1 antiplatelet 1041 (59.3) 4791 (65.5)
≥ 2 antiplatelets 668 (38.0) 2262 (30.9)
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Discussion
The results of the CLARIFY registry indicate that a large
proportion of patients with stable CAD in France receive
evidence-based therapies or treatments [15] for symptom
control and for prevention of cardiovascular events; the
ﬁndings are favourable in relation to CLARIFY patients in the
other Western European countries. Patients in France are
also more likely to go coronary intervention and are being
treated with more aggressive antiplatelet therapy, which
may reﬂect adherence to guidelines advocating treatment
with dual antiplatelet therapy for 9—12months following
stent implantation [18]. Nevertheless, there remains room
for improvement, illustrated by the fact that some patients
still present angina episodes, albeit at a lower rate in France
than in other Western European countries. Furthermore,
while patients in France exhibit lower mean heart rates and
higher rates of physical activity than their counterparts in
other Western European countries, the mean heart rate of
French patients is still somewhat high, and a substantial pro-
portion of French patients report either no physical activity
or only light levels of exercise.
The objective of managing stable CAD — through a
combination of risk factor control, pharmacological ther-
apy, lifestyle improvements, and patient education— is to
reduce the patient’s symptoms and improve their prognosis.
Lifestyle modiﬁcations include smoking cessation, healthy
diet, regular physical activity, maintaining a healthy weight,
and achieving targets for lipids, blood pressure, and glu-
cose [15]. Optimal medical therapy for patients with stable
CAD involves at least one drug to manage symptoms of
angina or ischaemia alongside drugs to prevent a coronary
event [15]. Low-dose aspirin (or clopidogrel, in the case
d
C
(459
f aspirin intolerance) and statins are recommended in all
atients with stable CAD, whereas angiotensin-converting
nzyme inhibitors or angiotensin II receptor blockers are
ecommended for stable CAD patients with another condi-
ion such as heart failure, hypertension, or diabetes. The
LARIFY registry data show that patients in France tend
o have good blood pressure control, whereas low-density
ipoprotein cholesterol is slightly higher than the rec-
mmended target of < 1.8mmol/L [15]. About two-thirds
f the patients achieved the LDL-cholesterol levels that
ere recommended at the time (< 2.60mmol/L, 100mg/dL)
19], and only approximately one-ﬁfth the levels currently
ecommended in the European guidelines (< 1.8mmol/L,
0mg/dL) [15] despite the fact that 95.8% of patients were
eceiving some form of lipid-lowering therapy. Current rec-
mmendations on optimal management of lipids diverge
etween the European guidelines, recommending a tar-
et level < 1.8mmol/L, and the American guidelines [20],
uggesting to abandon any target altogether, but recom-
ending to use the maximal tolerated dose of statins for any
atient with documented coronary artery disease. The dose
f statins was not recorded in CLARIFY, but the fact that the
ean LDL-cholesterol level was 2.3mmol/L suggests that
nly a minority of the patients received high-dose statins.
Of interest is the high rate of use of thienopyridines in
rance, which likely reﬂects the higher rate of percutaneous
ntervention and subsequent need for dual antiplatelet ther-
py. This ﬁnding is consistent with data from the World
ealth Organization MONICA (monitoring trends and deter-
inants in cardiovascular disease) Project, from the late
990s, which reported more intensive therapy in patients
ith a myocardial infarction in France when compared with
ther European regions [21,22]. The use of antiarrhythmic
rugs and oral anticoagulants is also somewhat high in view
f the slightly lower prevalence of a history of atrial ﬁbril-
ation or ﬂutter in the study and the fact that antiplatelets
re preferred to oral anticoagulants for prevention of throm-
otic events in patients without arrhythmias.
Contemporary data on the management and outcomes of
atients with stable CAD are sparse. The Euro Heart Sur-
ey (EHS) of Newly Presenting Angina, conducted in 2002
nd involving 3779 patients from Northern, Central, Western
nd Mediterranean Europe (20 from France) [23], identi-
ed a substantial gap between evidence-based therapies
nd implementation in practice [24]. These Western Euro-
ean data from CLARIFY indicate that progress has been
ade over the past decade, with much greater use of
spirin (52% in EHS vs. 84.8% in CLARIFY), beta-blockers (52%
s. 72.5%), calcium antagonists (18% vs. 25.4%), and lipid-
owering therapy (statin 30%, other lipid-lowering therapy
% vs. 93.1%) [24]. The population proﬁle has also changed
ver this period: in the CLARIFY Western European popu-
ation, patients with stable CAD are on average older than
hose in the EHS (66.2 vs. 61 years), have a higher propor-
ion of men (79.6% vs. 51%), are less likely to be current
mokers (11.4% vs. 29%), but are much more likely to have
iabetes (26.5% vs. 16%), dyslipidaemia (76.7% vs. 47%), and
eripheral artery disease (12.5% vs. 7%) [23]. Our ﬁndings aree patients COROnariens stables en région NORd-pas-de-
alais) study, which involved 4184 patients with stable CAD
including those with serious, potentially life-threatening
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ardiovascular or non-cardiovascular illnesses) in Northern
rance [25]. The CORONOR study reported an annual total
ortality of 3.3%, the same as that expected for the general
opulation, with only 41% of deaths being cardiovascular in
rigin. These ﬁndings are reassuring when taken in context
ith the high rates of use of secondary prevention strategies
25].
As expected from the distribution of alcohol consumption
n the general population in European countries at the time
he patients were included [26], there was no signiﬁcant dif-
erence in the number of drinks per week between France
nd the rest of Europe. Unfortunately, the type of alcohol
as not recorded in the study, so that possible differences
n this regard (in particular, wine versus other alcoholic bev-
rages) could not be studied.
The overall rate of peripheral artery disease in our West-
rn European population is driven by the high prevalence
n the French cohort. This rate is substantially higher than
hat in the global CLARIFY population (2825/30,493, 9.3%),
ut is also higher than the rates reported in other stud-
es conducted in France. For example, in a study of 710
en (mean age 60.9 years) with stable CAD from Southwest
rance conducted between 2001 and 2004, the prevalence
f peripheral artery disease was 11.7% compared with 17.6%
n the CLARIFY French cohort [27]. In the more recent
AST-MI (French registries of Acute ST-elevation and non-
T-elevation Myocardial Infarction) 2010 study, involving
079 patients with acute myocardial infarction enrolled
rom throughout the French territory, the prevalence of
eripheral artery disease was 8% [28]. These differences
n prevalence suggest the possibility of selection bias in
he CLARIFY French cohort. Irrespective of this possibility,
hile the overall risk factor proﬁle of the patients in France
as slightly better than that in the other Western European
ountries in CLARIFY, the rise in prevalence of some risk
actors over the past decade is of concern.
These contemporary Western European data demon-
trate the impact of improvements in the diagnosis and
anagement of acute coronary syndromes over the past
0 years, which have translated into reductions in associ-
ted acute and chronic mortality rates [10,21,22]. These
mprovements have not only changed the proﬁle of patients
ith established CAD, but have led to an increasing popula-
ion who would beneﬁt from evidence-based management.
imitations
s an observational registry, this study is subject to sev-
ral limitations, including missing data and the potential for
election bias. Data on drug dosage and on adverse effects
elated to the use of medications were not collected; nei-
her was information collected on the reasons for not using
edications or undergoing cardiac interventions.
onclusions
hese observational data from the CLARIFY registry indi-
ate good adherence to evidence-based guidelines in French
utpatients with stable CAD. A minority of patients do, how-
ver, still have symptoms of angina. Furthermore, while the
revalence of some cardiovascular risk factors has declinedN. Danchin et al.
ver the past decade, others show an increase, revealing
he need for better patient education regarding lifestyle
mprovements.
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